Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/197342
Title: | Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel |
Author: | Jimenez, Natalia Reig Torras, Oscar Marin Aguilera, Mercedes Aversa, Caterina Ferrer Mileo, Laura Font, Albert Rodriguez Vida, Alejo Climent, Miguel Ángel Cros, Sara Chirivella, Isabel Domenech, Montserrat Figols, Mariona González Billalabeitia, Enrique Jiménez Peralta, Daniel Rodriguez Carunchio, Leonardo Garcia Esteve, Samuel García de Herrero, Marta Ribal, Maria J. Prat Aparicio, Aleix Mellado González, Begoña |
Keywords: | Càncer de pròstata Andrògens Prostate cancer Androgens |
Issue Date: | 29-Sep-2022 |
Publisher: | MDPI |
Abstract: | Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3-0.9; p = 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4-0.9; p = 0.019) and OS (HR 0.5, 95% CI 0.2-0.9, p = 0.024), and lower expression of tumor suppressor genes (TSG) (RB1, PTEN and TP53) with shorter OS (HR 2, 95% CI 1-3.8; p = 0.044). ARV7 expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1-2.1, p = 0.008) and OS (HR 1.8, 95% CI 1.2-2.6, p = 0.004), high ESR2 was associated with longer OS (HR 0.5, 95% CI 0.2-1, p = 0.048) and low expression of RB1 was independently associated with shorter OS (HR 1.9, 95% CI 1.1-3.2, p = 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as ARV7, RB1, and ESR2 expression, have a prognostic value in mHSPC patients treated with ADT+DX. |
Note: | Reproducció del document publicat a: https://doi.org/10.3390/cancers14194757 |
It is part of: | Cancers, 2022, 14, 19, 4757-NA |
URI: | http://hdl.handle.net/2445/197342 |
Related resource: | https://doi.org/10.3390/cancers14194757 |
ISSN: | 2072-6694 |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Transcriptional Profile Associated with Clinical Outcomes_Cancers.pdf | 7.27 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License